Crossmark

Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2025.502396

Published Print: 2025-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

da Costa Ferreira, Sandro

Parra, Rogério Serafim

Sassaki, Ligia Yukie

Parente, José Miguel Luz

de Mello, Munique Kurtz

Chebli, Liliana Andrade

Luporini, Rafael Luís

Alves Junior, Antonio José Tiburcio

Firmino Nóbrega, Fernando Jorge

da Silva, Bruno César

Miranda, Eron Fábio

Quaresma, Abel Botelho

Nicollelli, Guilherme Mattioli

Gasparini, Rodrigo Galhardi

Dutra, Renata de Medeiros

Vasconcelos, Juarez Roberto de Oliveira

da Silva, Katia da Conceição

Magro, Daniéla Oliveira

Imbrizi, Marcello Rabello

Nagasako, Cristiane Kibune

Féres, Omar

Troncon, Luiz Ernesto de Almeida

Kotze, Paulo Gustavo

Chebli, Júlio Maria Fonseca
Funding

Funding for this research was provided by:

Fundação de Apoio ao Ensino, Pesquisa e Assistência
License Information

Text and Data Mining valid from 2025-11-01

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-02-25
More Information

This article is maintained by: Elsevier

Article Title: Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2025.502396

Content Type: article

Copyright: © 2025 The Authors. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below